The Future of Cancer Care: The Role of Biomarkers in Advancing Personalized Medicine
The American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society, is the nation’s leading cancer advocacy organization working every day to make cancer issues a top priority. ACS CAN unites and empowers cancer patients, survivors, caregivers, and their loved ones, giving them the tools and training they need to be heard. ACS CAN’s public policy priorities are focused on the actions that elected leaders at all levels of government can take to accelerate the ability to save lives and win the fight against cancer.
ACS CAN is hosting our 4th annual Connecticut public policy forum on November 14, 2019 at the Pond House Café in West Hartford CT. The goal is to create a dialogue to analyze and discuss how biomarkers are helping to change the healthcare landscape– particularly people living with cancer-- from a “one size-fits all” model to a more personalized approach where cancer and disease may be diagnosed earlier and treated using information contained within a patient’s own genetic profile, offering the potential to reduce health care costs and significantly improve patient outcomes.
Focus of the forum
This event will examine the current impact and future potential of biomarkers in cancer research, diagnosis and treatment and discuss advancements and barriers to new technological discoveries. Participants will include key stakeholders throughout the oncology community, including leaders in life sciences, health care systems, academia, provider groups, patient advocacy, public policy, business, and others. ACS CAN will use this event to help illustrate and explore the following:
- How can cancer patients benefit from genetic testing and targeted therapies and what role do biomarkers serve in the development of new medicines and treatments?
- What long-term investments in the development of sustainable initiatives and infrastructures are necessary to facilitate biomarker discovery and development?
- The “real” impact these technologies will have on the quality, delivery and patient experience of care;
- Drug development and reimbursement procedures;
- The future direction of technological innovation in the fight against cancer.
Jairaj A. Puthenveettil, Ph.D., M.B.A- Associate Director, Oncology Health Systems Bristol-Myers Squibb
Barbara Moehring - Director of Clinical Development and Medical Affairs Oncology at Boehringer Ingelheim
We would like to thank our Sponsors:
Please contact Bryte Johnson at [email protected] for more information regarding sponsorship opportunities.